行情

ADMS

ADMS

Adamas Pharma
NASDAQ

实时行情|Nasdaq Last Sale

5.88
-0.02
-0.34%
盘后: 5.85 -0.03 -0.51% 18:31 01/17 EST
开盘
5.94
昨收
5.90
最高
6.06
最低
5.80
成交量
45.08万
成交额
--
52周最高
12.57
52周最低
3.350
市值
1.64亿
市盈率(TTM)
-1.4588
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADMS 新闻

  • Lululemon:谜题待解
  • 界面.1小时前
  • 复飞之路再现波折 波音737Max软件又曝新缺陷
  • 中国新闻网.2小时前
  • 特朗普公布弹劾案辩护团队 参议院审理流程一览
  • 中国新闻网.3小时前
  • 美参院启动弹劾案 特朗普新聘三位律师
  • 央视.3小时前

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

ADMS 简况

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
展开

Webull提供Adamas Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。